nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.379	1	CbGbCtD
Duloxetine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0225	0.152	CbGeAlD
Duloxetine—Oesophageal stenosis—Riluzole—amyotrophic lateral sclerosis	0.0203	0.0505	CcSEcCtD
Duloxetine—White blood cell count increased—Riluzole—amyotrophic lateral sclerosis	0.0156	0.0389	CcSEcCtD
Duloxetine—NPY1R—nerve—amyotrophic lateral sclerosis	0.0147	0.0994	CbGeAlD
Duloxetine—Trismus—Riluzole—amyotrophic lateral sclerosis	0.00939	0.0234	CcSEcCtD
Duloxetine—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.00842	0.021	CcSEcCtD
Duloxetine—Yawning—Riluzole—amyotrophic lateral sclerosis	0.00778	0.0194	CcSEcCtD
Duloxetine—Naftifine—SIGMAR1—amyotrophic lateral sclerosis	0.00673	0.624	CrCbGaD
Duloxetine—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00669	0.0167	CcSEcCtD
Duloxetine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0062	0.0418	CbGeAlD
Duloxetine—NPY1R—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.00606	0.0999	CbGpPWpGaD
Duloxetine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00586	0.0396	CbGeAlD
Duloxetine—HTR2A—pons—amyotrophic lateral sclerosis	0.00579	0.0391	CbGeAlD
Duloxetine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00553	0.0138	CcSEcCtD
Duloxetine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00553	0.0138	CcSEcCtD
Duloxetine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00539	0.0134	CcSEcCtD
Duloxetine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00533	0.0133	CcSEcCtD
Duloxetine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00521	0.013	CcSEcCtD
Duloxetine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.005	0.0337	CbGeAlD
Duloxetine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00494	0.0333	CbGeAlD
Duloxetine—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00478	0.0119	CcSEcCtD
Duloxetine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00478	0.0119	CcSEcCtD
Duloxetine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00464	0.0313	CbGeAlD
Duloxetine—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00456	0.0114	CcSEcCtD
Duloxetine—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.00453	0.0746	CbGpPWpGaD
Duloxetine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00439	0.0109	CcSEcCtD
Duloxetine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00435	0.0108	CcSEcCtD
Duloxetine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00435	0.0108	CcSEcCtD
Duloxetine—Mania—Riluzole—amyotrophic lateral sclerosis	0.00431	0.0107	CcSEcCtD
Duloxetine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00425	0.0287	CbGeAlD
Duloxetine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00424	0.0286	CbGeAlD
Duloxetine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00416	0.0104	CcSEcCtD
Duloxetine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00416	0.0104	CcSEcCtD
Duloxetine—Fluoxetine—SIGMAR1—amyotrophic lateral sclerosis	0.00405	0.376	CrCbGaD
Duloxetine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00403	0.01	CcSEcCtD
Duloxetine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00385	0.026	CbGeAlD
Duloxetine—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00381	0.0095	CcSEcCtD
Duloxetine—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00378	0.00943	CcSEcCtD
Duloxetine—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00373	0.00929	CcSEcCtD
Duloxetine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00871	CcSEcCtD
Duloxetine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00843	CcSEcCtD
Duloxetine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00826	CcSEcCtD
Duloxetine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00826	CcSEcCtD
Duloxetine—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00826	CcSEcCtD
Duloxetine—NPY1R—nervous system—amyotrophic lateral sclerosis	0.00331	0.0223	CbGeAlD
Duloxetine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00801	CcSEcCtD
Duloxetine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00319	0.00796	CcSEcCtD
Duloxetine—NPY1R—central nervous system—amyotrophic lateral sclerosis	0.00319	0.0215	CbGeAlD
Duloxetine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00791	CcSEcCtD
Duloxetine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00782	CcSEcCtD
Duloxetine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00772	CcSEcCtD
Duloxetine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00772	CcSEcCtD
Duloxetine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00306	0.00764	CcSEcCtD
Duloxetine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00755	CcSEcCtD
Duloxetine—HTR2A—nerve—amyotrophic lateral sclerosis	0.003	0.0203	CbGeAlD
Duloxetine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00707	CcSEcCtD
Duloxetine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00665	CcSEcCtD
Duloxetine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00665	CcSEcCtD
Duloxetine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00266	0.0179	CbGeAlD
Duloxetine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00264	0.00659	CcSEcCtD
Duloxetine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00652	CcSEcCtD
Duloxetine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00652	CcSEcCtD
Duloxetine—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00257	0.0173	CbGeAlD
Duloxetine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00631	CcSEcCtD
Duloxetine—NPY1R—brain—amyotrophic lateral sclerosis	0.00253	0.0171	CbGeAlD
Duloxetine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00626	CcSEcCtD
Duloxetine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00612	CcSEcCtD
Duloxetine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00244	0.0164	CbGeAlD
Duloxetine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00604	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00601	CcSEcCtD
Duloxetine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00599	CcSEcCtD
Duloxetine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00596	CcSEcCtD
Duloxetine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00581	CcSEcCtD
Duloxetine—HTR6—nervous system—amyotrophic lateral sclerosis	0.00233	0.0157	CbGeAlD
Duloxetine—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0057	CcSEcCtD
Duloxetine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00567	CcSEcCtD
Duloxetine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00567	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00567	CcSEcCtD
Duloxetine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00563	CcSEcCtD
Duloxetine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00225	0.0152	CbGeAlD
Duloxetine—HTR6—central nervous system—amyotrophic lateral sclerosis	0.00224	0.0151	CbGeAlD
Duloxetine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00558	CcSEcCtD
Duloxetine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00558	CcSEcCtD
Duloxetine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00548	CcSEcCtD
Duloxetine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0054	CcSEcCtD
Duloxetine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00538	CcSEcCtD
Duloxetine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00215	0.0145	CbGeAlD
Duloxetine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00534	CcSEcCtD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.00213	0.0351	CbGpPWpGaD
Duloxetine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00528	CcSEcCtD
Duloxetine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00524	CcSEcCtD
Duloxetine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00518	CcSEcCtD
Duloxetine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00513	CcSEcCtD
Duloxetine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00205	0.0138	CbGeAlD
Duloxetine—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00511	CcSEcCtD
Duloxetine—NPY1R—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00205	0.0337	CbGpPWpGaD
Duloxetine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00502	CcSEcCtD
Duloxetine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00201	0.005	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00201	0.005	CcSEcCtD
Duloxetine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0049	CcSEcCtD
Duloxetine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0049	CcSEcCtD
Duloxetine—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00481	CcSEcCtD
Duloxetine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0047	CcSEcCtD
Duloxetine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00459	CcSEcCtD
Duloxetine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00183	0.0301	CbGpPWpGaD
Duloxetine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00453	CcSEcCtD
Duloxetine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00452	CcSEcCtD
Duloxetine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00448	CcSEcCtD
Duloxetine—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.00179	0.0121	CbGeAlD
Duloxetine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00446	CcSEcCtD
Duloxetine—HTR6—brain—amyotrophic lateral sclerosis	0.00178	0.012	CbGeAlD
Duloxetine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00444	CcSEcCtD
Duloxetine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00437	CcSEcCtD
Duloxetine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00437	CcSEcCtD
Duloxetine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00431	CcSEcCtD
Duloxetine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00429	CcSEcCtD
Duloxetine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00426	CcSEcCtD
Duloxetine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00426	CcSEcCtD
Duloxetine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00425	CcSEcCtD
Duloxetine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00414	CcSEcCtD
Duloxetine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00412	CcSEcCtD
Duloxetine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00165	0.0112	CbGeAlD
Duloxetine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00162	0.0266	CbGpPWpGaD
Duloxetine—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.0016	0.0108	CbGeAlD
Duloxetine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00395	CcSEcCtD
Duloxetine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00393	CcSEcCtD
Duloxetine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00393	CcSEcCtD
Duloxetine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00391	CcSEcCtD
Duloxetine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00391	CcSEcCtD
Duloxetine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0039	CcSEcCtD
Duloxetine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00388	CcSEcCtD
Duloxetine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00387	CcSEcCtD
Duloxetine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00386	CcSEcCtD
Duloxetine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00385	CcSEcCtD
Duloxetine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00152	0.0102	CbGeAlD
Duloxetine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.0015	0.0101	CbGeAlD
Duloxetine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00371	CcSEcCtD
Duloxetine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00367	CcSEcCtD
Duloxetine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00364	CcSEcCtD
Duloxetine—HTR6—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—amyotrophic lateral sclerosis	0.00144	0.0238	CbGpPWpGaD
Duloxetine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00356	CcSEcCtD
Duloxetine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00355	CcSEcCtD
Duloxetine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00354	CcSEcCtD
Duloxetine—Chills—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00352	CcSEcCtD
Duloxetine—HTR2A—embryo—amyotrophic lateral sclerosis	0.00141	0.0095	CbGeAlD
Duloxetine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00351	CcSEcCtD
Duloxetine—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.0014	0.023	CbGpPWpGaD
Duloxetine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00139	0.0094	CbGeAlD
Duloxetine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00347	CcSEcCtD
Duloxetine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00344	CcSEcCtD
Duloxetine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00342	CcSEcCtD
Duloxetine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00337	CcSEcCtD
Duloxetine—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00135	0.00909	CbGeAlD
Duloxetine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00335	CcSEcCtD
Duloxetine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00335	CcSEcCtD
Duloxetine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00134	0.00905	CbGeAlD
Duloxetine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00332	CcSEcCtD
Duloxetine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00331	CcSEcCtD
Duloxetine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00329	CcSEcCtD
Duloxetine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00131	0.00885	CbGeAlD
Duloxetine—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.0013	0.00875	CbGeAlD
Duloxetine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.00129	0.0087	CbGeAlD
Duloxetine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0032	CcSEcCtD
Duloxetine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00128	0.00862	CbGeAlD
Duloxetine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00317	CcSEcCtD
Duloxetine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00316	CcSEcCtD
Duloxetine—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00127	0.0209	CbGpPWpGaD
Duloxetine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00314	CcSEcCtD
Duloxetine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00312	CcSEcCtD
Duloxetine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00308	CcSEcCtD
Duloxetine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00307	CcSEcCtD
Duloxetine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00123	0.0083	CbGeAlD
Duloxetine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00306	CcSEcCtD
Duloxetine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00306	CcSEcCtD
Duloxetine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00302	CcSEcCtD
Duloxetine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0012	0.003	CcSEcCtD
Duloxetine—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.0012	0.0198	CbGpPWpGaD
Duloxetine—Cough—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00298	CcSEcCtD
Duloxetine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00296	CcSEcCtD
Duloxetine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00295	CcSEcCtD
Duloxetine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00117	0.00793	CbGeAlD
Duloxetine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00291	CcSEcCtD
Duloxetine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00291	CcSEcCtD
Duloxetine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00291	CcSEcCtD
Duloxetine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0029	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00289	CcSEcCtD
Duloxetine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00287	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00115	0.0189	CbGpPWpGaD
Duloxetine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00285	CcSEcCtD
Duloxetine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00281	CcSEcCtD
Duloxetine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00112	0.00759	CbGeAlD
Duloxetine—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00112	0.0185	CbGpPWpGaD
Duloxetine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00279	CcSEcCtD
Duloxetine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00279	CcSEcCtD
Duloxetine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00277	CcSEcCtD
Duloxetine—Shock—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00274	CcSEcCtD
Duloxetine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00273	CcSEcCtD
Duloxetine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00273	CcSEcCtD
Duloxetine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00272	CcSEcCtD
Duloxetine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00271	CcSEcCtD
Duloxetine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00108	0.0073	CbGeAlD
Duloxetine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0027	CcSEcCtD
Duloxetine—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00108	0.0178	CbGpPWpGaD
Duloxetine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00266	CcSEcCtD
Duloxetine—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00107	0.0175	CbGpPWpGaD
Duloxetine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00107	0.00719	CbGeAlD
Duloxetine—HTR2C—brain—amyotrophic lateral sclerosis	0.00103	0.00695	CbGeAlD
Duloxetine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00254	CcSEcCtD
Duloxetine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00252	CcSEcCtD
Duloxetine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.001	0.0025	CcSEcCtD
Duloxetine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000994	0.00248	CcSEcCtD
Duloxetine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000985	0.00245	CcSEcCtD
Duloxetine—SLC6A4—brain—amyotrophic lateral sclerosis	0.000976	0.00659	CbGeAlD
Duloxetine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000972	0.00242	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000966	0.00241	CcSEcCtD
Duloxetine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000964	0.0024	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000963	0.0159	CbGpPWpGaD
Duloxetine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000957	0.00238	CcSEcCtD
Duloxetine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000957	0.00238	CcSEcCtD
Duloxetine—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00094	0.0155	CbGpPWpGaD
Duloxetine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000922	0.0023	CcSEcCtD
Duloxetine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000915	0.00228	CcSEcCtD
Duloxetine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000899	0.00607	CbGeAlD
Duloxetine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000889	0.00222	CcSEcCtD
Duloxetine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000884	0.0022	CcSEcCtD
Duloxetine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000884	0.0022	CcSEcCtD
Duloxetine—SLC6A2—brain—amyotrophic lateral sclerosis	0.000859	0.0058	CbGeAlD
Duloxetine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000824	0.00205	CcSEcCtD
Duloxetine—NPY1R—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000812	0.0134	CbGpPWpGaD
Duloxetine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000803	0.002	CcSEcCtD
Duloxetine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000802	0.00541	CbGeAlD
Duloxetine—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000796	0.0131	CbGpPWpGaD
Duloxetine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000791	0.00197	CcSEcCtD
Duloxetine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00191	CcSEcCtD
Duloxetine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00074	0.00184	CcSEcCtD
Duloxetine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000711	0.00177	CcSEcCtD
Duloxetine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00176	CcSEcCtD
Duloxetine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00176	CcSEcCtD
Duloxetine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000701	0.00175	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000686	0.0113	CbGpPWpGaD
Duloxetine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000676	0.00456	CbGeAlD
Duloxetine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000664	0.00166	CcSEcCtD
Duloxetine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000651	0.00439	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000646	0.0106	CbGpPWpGaD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.000639	0.0105	CbGpPWpGaD
Duloxetine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000636	0.00429	CbGeAlD
Duloxetine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000616	0.00415	CbGeAlD
Duloxetine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000593	0.004	CbGeAlD
Duloxetine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000579	0.00391	CbGeAlD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000572	0.00942	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000567	0.00935	CbGpPWpGaD
Duloxetine—HTR2A—brain—amyotrophic lateral sclerosis	0.000516	0.00349	CbGeAlD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000495	0.00816	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000492	0.0081	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000488	0.00804	CbGpPWpGaD
Duloxetine—CYP2D6—brain—amyotrophic lateral sclerosis	0.00047	0.00317	CbGeAlD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000442	0.00728	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000442	0.00728	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000442	0.00728	CbGpPWpGaD
Duloxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000439	0.00723	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000432	0.00712	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.00042	0.00692	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000415	0.00684	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000413	0.0068	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000364	0.006	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000357	0.00588	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000355	0.00584	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000336	0.00553	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000325	0.00535	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00032	0.00527	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000316	0.00521	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000305	0.00502	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000297	0.00489	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000297	0.00489	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000282	0.00464	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000279	0.0046	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000278	0.00458	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000276	0.00455	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000276	0.00455	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000275	0.00453	CbGpPWpGaD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000269	0.00444	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000266	0.00438	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000266	0.00438	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000266	0.00438	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000263	0.00433	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000257	0.00424	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000253	0.00416	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000252	0.00416	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00025	0.00412	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000249	0.0041	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000246	0.00405	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000246	0.00405	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000244	0.00402	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000238	0.00392	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000234	0.00386	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000229	0.00377	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000227	0.00375	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000225	0.00371	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000224	0.00368	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000215	0.00355	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000215	0.00354	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000211	0.00348	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000211	0.00348	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000209	0.00344	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000207	0.00342	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000199	0.00328	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000197	0.00324	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000191	0.00314	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000188	0.0031	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000185	0.00305	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000181	0.00299	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000175	0.00289	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000175	0.00289	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000175	0.00288	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00017	0.0028	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000164	0.0027	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000152	0.00251	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000151	0.00249	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000151	0.00248	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000149	0.00246	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000148	0.00244	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000138	0.00227	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000134	0.0022	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000134	0.0022	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000128	0.00211	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000128	0.00211	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000125	0.00205	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000121	0.002	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000116	0.00191	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000114	0.00188	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000114	0.00188	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000114	0.00188	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000114	0.00187	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000114	0.00187	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000113	0.00187	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.00011	0.00181	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000104	0.00172	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000104	0.00171	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000103	0.00169	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000102	0.00169	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000101	0.00167	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	9.88e-05	0.00163	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.71e-05	0.0016	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	9.69e-05	0.0016	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.61e-05	0.00158	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	9.31e-05	0.00153	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.24e-05	0.00152	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.15e-05	0.00151	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.13e-05	0.0015	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—C3—amyotrophic lateral sclerosis	7.92e-05	0.0013	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	7.84e-05	0.00129	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.83e-05	0.00129	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	7.78e-05	0.00128	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	7.73e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.66e-05	0.00126	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.55e-05	0.00124	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.36e-05	0.00121	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.26e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	6.87e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.86e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.82e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	6.65e-05	0.0011	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.64e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	6.56e-05	0.00108	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.55e-05	0.00108	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.51e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.47e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.27e-05	0.00103	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.26e-05	0.00103	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.06e-05	0.000998	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	6.01e-05	0.000989	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	6.01e-05	0.000989	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	5.98e-05	0.000985	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	5.95e-05	0.000981	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	5.83e-05	0.000961	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.83e-05	0.000961	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.56e-05	0.000916	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.5e-05	0.000906	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	5.49e-05	0.000905	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.34e-05	0.00088	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.11e-05	0.000841	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.09e-05	0.000838	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.09e-05	0.000838	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.06e-05	0.000834	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.03e-05	0.000828	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.01e-05	0.000825	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	4.8e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.76e-05	0.000785	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.74e-05	0.000781	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.65e-05	0.000766	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.64e-05	0.000765	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.61e-05	0.00076	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.6e-05	0.000757	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.48e-05	0.000737	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.36e-05	0.000719	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	4.34e-05	0.000715	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.33e-05	0.000713	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.14e-05	0.000681	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.1e-05	0.000675	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.07e-05	0.00067	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.06e-05	0.000669	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.05e-05	0.000667	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.01e-05	0.00066	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.85e-05	0.000635	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.78e-05	0.000623	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.68e-05	0.000606	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.64e-05	0.0006	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.56e-05	0.000586	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.54e-05	0.000584	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.52e-05	0.000579	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.39e-05	0.000558	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.38e-05	0.000556	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.3e-05	0.000543	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	3.29e-05	0.000542	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.27e-05	0.000539	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	3.04e-05	0.0005	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.99e-05	0.000493	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.94e-05	0.000484	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.89e-05	0.000476	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.86e-05	0.000471	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.79e-05	0.000459	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.78e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.72e-05	0.000447	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.61e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.6e-05	0.000428	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.57e-05	0.000424	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.49e-05	0.000411	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.49e-05	0.000409	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.47e-05	0.000407	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.42e-05	0.000398	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.4e-05	0.000395	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.34e-05	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.27e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.24e-05	0.000368	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.16e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.13e-05	0.00035	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.11e-05	0.000348	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2e-05	0.00033	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.93e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.85e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.85e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.77e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	0.000286	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.65e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.54e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.43e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.42e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.36e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.34e-05	0.000221	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.34e-05	0.000221	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.32e-05	0.000218	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.23e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.21e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.18e-05	0.000195	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.14e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.05e-05	0.000172	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.04e-05	0.000172	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.01e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.89e-06	0.000163	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.12e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.09e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.88e-06	0.000146	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.59e-06	0.000142	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	8.59e-06	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.71e-06	0.000127	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.94e-06	0.000114	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.71e-06	0.000111	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.88e-06	9.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.83e-06	9.6e-05	CbGpPWpGaD
